237 filings
Page 7 of 12
424B5
hjqsx84mtfn64wpuj6w
21 Jun 18
Prospectus supplement for primary offering
4:17pm
FWP
iavno89o7ogx3r0wtcdu
18 Jun 18
Free writing prospectus
6:41am
424B5
coghl
18 Jun 18
Prospectus supplement for primary offering
6:37am
6-K
ge0os0xnsg8ho
18 Jun 18
Current report (foreign)
6:35am
6-K
tohs54st sfpy4sk9vcq
12 Jun 18
Galmed’s 600 mg AramcholTM Achieved a Regulatory Approvable Endpoint Showing NASH
7:00am
6-K
ui299r8kyvon4nce9v
9 May 18
Galmed Pharmaceuticals Provides Business Update and Reports First Quarter 2018 Financial Results
7:00am
6-K
j41r baxjleal8
4 Apr 18
Current report (foreign)
12:00am
424B5
5oyox036
4 Apr 18
Prospectus supplement for primary offering
12:00am
6-K
4kom0b0mvm5uc7asta
3 Apr 18
Galmed Pharmaceuticals Announces Pricing of $6.0 Million Registered Direct Offering
12:00am
UPLOAD
rh426e5jsx1
2 Apr 18
Letter from SEC
12:00am
CORRESP
vvq6jbjq1khk7zld
2 Apr 18
Correspondence with SEC
12:00am
EFFECT
17qnkhbxpn749ci hp
2 Apr 18
Notice of effectiveness
12:00am
F-3
4mvbx
26 Mar 18
Shelf registration (foreign)
12:00am
6-K
78dqiylfl0u
13 Mar 18
Galmed Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
12:00am
6-K
5vr0k7tfbdt00t0u
14 Feb 18
Galmed Announces ARRIVE Study Data
12:00am
6-K
4qyb697
7 Feb 18
Galmed Granted "Preferred Technological Enterprise" Status Which
12:00am
6-K
8l0e6smu 1ca89
3 Jan 18
Current report (foreign)
12:00am
6-K
fpllkox1hf
2 Jan 18
Current report (foreign)
12:00am
6-K
co85 dkhjavzbeg
22 Dec 17
Current report (foreign)
12:00am